Korea Needs ‘More Unified’ Bio-Health Care Policy: Experts
This article was originally published in PharmAsia News
Executive Summary
At a recent seminar in Seoul, South Korean biotechnology and health care experts positively assessed the government's ongoing efforts to nurture the sector, but called for more unified policies and clearer objectives going forward.
You may also be interested in...
Korean Pharma Calls For New Policy ‘Control Tower’, More Support
Amid the recent ousting of President Park Geun-hye amid corruption allegations and a new presidential election only weeks away, the South Korean pharma industry is quickening its calls for policy support from the next administration by recommending a variety of changes.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.